Thursday, February 2, 2017

UPDATE 2-AstraZeneca faces falling profit while awaits key drug data

* All eyes on mid-year results from lung cancer trial

(Adds shares, further details on cancer drug competition)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)